Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Reumatologia Clinica|July 6, 2025
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registryClementina López-Medina, Lucía Otero-Varela, Fernando Sánchez-Alonso, et al.
Musculoskeletal Care|August 23, 2022
Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritisManuel Pombo-Suárez, Daniel Seoane-Mato, Federico Díaz-González, et al.
Rheumatology and Therapy|April 25, 2022
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER RegistryManuel José Moreno-Ramos, Carlos Sanchez-Piedra, Olga Martínez-González, et al.
Rheumatology (Oxford, England)|October 22, 2025
Cancer risk in patients with rheumatoid arthritis receiving biologic and targeted synthetic disease modifying antirheumatic drugs: results from the BIOBADASER III registryJuan Molina-Collada, Lucía Otero-Varela, Paloma Vela, et al.
Reumatologia Clinica|September 28, 2024
Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritisJosé María Álvaro-Gracia Álvaro, Petra Díaz Del Campo Fontecha, José Luis Andréu Sánchez, et al.
Arthritis Research & Therapy|May 14, 2025
Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis: Data from BIOBADASER III registryPaloma Vela-Casasempere, Lucía Otero-Varela, Silvia Gómez Sabater, et al.
Reumatologia Clinica|September 9, 2022
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosisJosé Antonio Rodríguez Portal, Noé Brito García, Petra Díaz Del Campo Fontecha, et al.
Reumatologia Clinica|September 6, 2022
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: TreatmentJavier Narváez, Petra Díaz Del Campo Fontecha, Noé Brito García, et al.
Reumatologia Clinica|June 26, 2022
Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodologyJavier Narváez, Myriam Aburto, Daniel Seoane-Mato, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 6, 2025
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in patients with rheumatological diseasesMaria Giulia Caponcello, Paula Olivares Navarro, Cecilia Bonazzetti, et al.
Pageof 12